



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO.	APPLICATION NO
		011068-033-999	09/766,344
		APPLICANT	
		Parkin <i>et al.</i>	
FILING DATE		GROUP	
January 19, 2001		1648	

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SF	B01	6,033,902	3/7/00	Haseltine <i>et al.</i>	435	320.1	
SF	B02	6,242,187 B1	06/05/01	Capon <i>et al.</i>	435	6	

**FOREIGN PATENT DOCUMENTS**


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
SF	B03	Int'l Search Report for PCT/US03/21355	5/3/04	PCT					

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

--	--	--

EXAMINER	<i>Shawn Jol</i>	DATE CONSIDERED	<i>11/26/04</i>
----------	------------------	-----------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	11068-033-999	09/766,344
	APPLICANT	
	Parkin <i>et al.</i>	
	FILING DATE	GROUP
	January 19, 2001	1648

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SF	B01	5,436,131	7/95	Condra <i>et al.</i>	435	7.4	
	B02	5,766,842	6/98	Melnick <i>et al.</i>	442	794	
	B03	6,033,902	3/00	Haseltine <i>et al.</i>	435	300.1	
	B04	6,103,462	8/00	Paulous <i>et al.</i>	435	5	
	B05	6,242,187	6/01	Capon <i>et al.</i>	435	6	
	B06	20030108857	6/03	Parkin <i>et al.</i>	—	—	
SF	B07	20040106106	6/04	Parkin <i>et al.</i>	—	—	

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
SF	B08	WO99/67427	6/99	PCT	—	—			
	B09	WO00/78996	12/00	PCT	—	—			
	B10	WO02/22076	3/02	PCT	—	—			
	B11	WO02/068618	9/02	PCT	—	—			
	B12	WO02/099387	12/02	PCT	—	—			
	B13	WO03/070700	8/03	PCT	—	—			
	B14	WO04/003512	1/04	PCT	—	—			
	B15	WO04/003514	1/04	PCT	—	—			
	B16	Int'l Search Report for PCT/US02/18684	1/03	PCT	—	—			
	B17	Int'l Search Report for PCT/US03/04362	12/04	PCT	—	—			
	B18	Int'l Search Report for PCT/US03/21335	5/04	PCT	—	—			
SF	B19	Int'l Search Report for PCT/US03/21023	7/04	PCT	—	—			

### OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

SF	B20	Carrillo <i>et al.</i> , (1998), "In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants With Increased Resistance to ABT-378, a Novel Protease Inhibitor," <i>Journal of Virology</i> , 72(9): 7532-41.
	B21	Condra <i>et al.</i> , (1996), "Genetic Correlates of In Vivo Resistance to Indinavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor," <i>Journal of Virology</i> , 70(12): 8270-76
	B22	Genbank Accession Number P12497 POL Polyprotein (2004)
	B23	Genbank Accession Number AF324493 HIV-1 vector pNL4...[gi:12831134] (2001).
	B24	Gervais, <i>et al.</i> , (1997), "A New Reporter Cell Line to Monitor HIV Infection and Drug Susceptibility <i>in Vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 94: 4653-4658.
	B25	Gong <i>et al.</i> , (2000), "In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632," <i>Antimicrobial Agents and Chemotherapy</i> , 44(9): 2319-26.
SF	B26	Gunthard, <i>et al.</i> , (1998), "Comparative Performance of High-Density Oligonucleotide Sequencing and Dideoxynucleotide Sequencing of HIV Type 1 <i>pol</i> From Clinical Samples," <i>Aids Research and Human Retroviruses</i> .



		14(10): 869-876.
	B28	Haubrich <i>et al.</i> , (2001), "CCTG 575: A Randomized, Prospective Study of Phenotype Testing Versus Standard of Care For Patients Failing Antiretroviral Therapy," <i>Antiviral Therapy</i> , 6(Supplement 1): 63.
	B29	Herrmann, <i>et al.</i> , (1997), "A Working Hypotheses-Virus Resistance Development As An Indicator of Specific Antiviral Activity," <i>Ann. NY Acad Sciences</i> , 284: 632-637.
	B30	Hirsch, <i>et al.</i> , (2000), "Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection" <i>JAMA</i> , 283(18): 2417-26.
	B31	Katzenstein <i>et al.</i> , (2002), "Baseline Phenotypic Susceptibility and Virologic failure over 144 weeks Among Nucleoside RT Inhibitor Experienced Subjects in ACTG 364," <i>Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection</i> ," 2002 9 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Session 77 Poster Session 591-T.
	B32	Katzenstein <i>et al.</i> , (2002), "The Inhibitory Quotient (IQ) for Saquinavir (SQV) Predicts Virologic Response to Salvage Therapy," 2002 9 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Session 28 Poster Session 129.
	B33	Kempf <i>et al.</i> , (2001), "Identification of Genotypic Changes in Human Immunodeficiency Virus Protease that Correlate With Reduced Susceptibility to the Protease Inhibitor Lopinavir Among Viral Isolates From Protease Inhibitor-Experienced Patients," <i>Journal of Virology</i> , 75(16): 7462-69.
	B34	Maguire <i>et al.</i> , (2002), "Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 46(3): 731-738.
	B35	Petropoulos, <i>et al.</i> , (2000), "A Novel Phenotypic Drug Susceptibility Assay For Human Immunodeficiency Virus Type 1," <i>Antimicrobial Agents and Chemotherapy</i> , 44(4): 920-928.
	B36	Race, <i>et al.</i> , (1999), "Analysis of HIV Cross-Resistance to Protease Inhibitors Using A Rapid Single-Cycle Recombinant Virus Assay For Patients Failing On Combination Thérapies," <i>AIDS</i> , 13(15): 2061-2068.
	B37	Rusconi, Stefano. <i>et al.</i> (2000): "Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived From Patients with Multidrug Resistance to Other Protease Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 44(5): 1328-32.
	B38	Schuurman, <i>et al.</i> , (1999), "Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <i>Journal of Clinical Microbiology</i> , 37(7): 2291-2296.
GP	B39	Shi, <i>et al.</i> , (1997), "A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to reverse Transcriptase Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 41(12): 2781-85.
EXAMINER		DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.